JAB-2485, independently developed by the Beijing Economic & Technological Development Area (BDA) enterprise Jacobio Pharmaceuticals, was approved in the United States for clinical trial application for treatment of various advanced solid tumors on Jan 17, 2022.

JAB-2485 is a highly selective small molecule Aurora A inhibitor. It can inhibit Aurora A activity at the cellular level and inhibit tumor growth. There is currently no similar product in the world that is commercially available. It  is the third Aurora A inhibitor to be clinically tested in the United States.

Based in the BDA, Jacobio is committed to providing patients with breakthrough treatment solutions. 

Its mission is to be an innovator of biomedicine, providing effective and innovative treatments for patients around the world, and works together with partners to become a globally recognized leader in drug development. 

Currently, the Jacobio experimental platform has the technology to develop allosteric inhibitors of protein phosphatases, KRAS and other transcription factors.